Incidence of Cytomegalovirus in Moderate Risk Kidney Transplant Recipients Receiving Low Dose Valganciclovir.

被引：0
|
作者：
Fallah, T. [1 ]
Logan, A. [2 ]
Garcia, L. Beltran [3 ]
Bowman, L. [2 ]
机构：
[1] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA
[2] Tampa Gen Hosp, Tampa, FL 33606 USA
[3] Tampa Gen Hosp, Florida Kidney Phys, Tampa, FL 33606 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2019年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
A326
引用
下载
收藏
页码：722 / 722
页数：1
相关论文
共 50 条
  • [41] African American Race Is an Independent Risk Factor for Cytomegalovirus Infection in Renal Transplant Recipients on Low-Dose Valganciclovir Prophylaxis
    Patel, S.
    Kuten, S.
    Loucks-DeVos, J.
    Knight, R.
    Gaber, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [42] The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
    Humar, A.
    Lebranchu, Y.
    Vincenti, F.
    Blumberg, E. A.
    Punch, J. D.
    Limaye, A. P.
    Abramowicz, D.
    Jardine, A. G.
    Voulgari, A. T.
    Ives, J.
    Hauser, I. A.
    Peeters, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (05) : 1228 - 1237
  • [43] The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients
    Jorgenson, Margaret R.
    Descourouez, Jillian L.
    Garg, Neetika
    Parajuli, Sandesh
    Mandelbrot, Didier A.
    Odorico, Jon S.
    Saddler, Christopher M.
    Smith, Jeannina A.
    TRANSPLANT INFECTIOUS DISEASE, 2021,
  • [44] PREEMPTIVE THERAPY VERSUS UNIVERSAL PROPHYLAXIS WITH VALGANCICLOVIR IN MINIMIZING THE RISK OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS
    Khan, Muhammad Tassaduq
    SWISS MEDICAL WEEKLY, 2019, : 19S - 19S
  • [45] Safety and Effectiveness of Low-Dose Cytomegalovirus Valganciclovir Prophylaxis in CMV Seropositive Lung Transplant Recipients
    Lehikoinen, R. A.
    Syrjala, S.
    Heliovaara, E.
    Tikkanen, J.
    Lemstrom, K.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04): : S486 - S486
  • [46] Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients
    Park, JM
    Lake, KD
    Arenas, JD
    Fontana, RJ
    LIVER TRANSPLANTATION, 2006, 12 (01) : 112 - 116
  • [47] Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients
    Bixby, Alexandra L.
    Fitzgerald, Linda
    Park, Jeong M.
    Kaul, Daniel
    Tischer, Sarah
    TRANSPLANT INFECTIOUS DISEASE, 2021, 23 (05)
  • [48] Standard Dose Valganciclovir Prophylaxis for High-Risk Kidney Transplant Recipients Reduces Incidences of Breakthrough and Resistant Cytomegalovirus Infection.
    Huang, Y.
    Park, J.
    Naik, A.
    Kaul, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 777 - 777
  • [49] EXTENDED EFFICACY OF LOW-DOSE VALGANCICLOVIR FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE IN INTERMEDIATE-RISK KIDNEY TRANSPLANT RECIPIENTS-TWO YEARS FOLLOW UP
    Aly, Medhat
    Gheith, Osama
    Fathi, Ahmed
    Makkeya, Yahya
    Said, Tarek
    Nair, Prasad
    Al-Otaibi, Torki
    TRANSPLANT INTERNATIONAL, 2017, 30 : 366 - 367
  • [50] Efficacy and safety of low-dose valganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients.
    Park, JM
    Arenas, JD
    Fontana, RJ
    Lake, KD
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 502 - 502
12345